Neurology · NF2-related schwannomatosis

Tumors and Physical Manifestations

At a Glance

NF2-related schwannomatosis causes non-cancerous tumors to grow in critical areas like the brain and spinal cord. The hallmark sign is bilateral vestibular schwannomas, which affect hearing and balance. Regular monitoring is essential to manage nerve pressure, pain, and quality of life.

In NF2-related schwannomatosis, the term “benign” can be misleading. While these tumors are non-cancerous—meaning they do not spread to distant organs—they grow in “high-rent” areas of the body, such as the brain and spinal cord ^[1]. Because they grow within the tight spaces of the skull and spinal column, even a small amount of growth can put significant pressure on vital nerves, leading to serious physical challenges ^[2]^[3].

The Hallmark: Bilateral Vestibular Schwannomas

The “pathognomonic” feature of this condition—meaning it is so characteristic that its presence almost confirms the diagnosis—is the development of bilateral vestibular schwannomas (BVS) ^[4]^[5].

What they are: These are tumors that grow on the vestibular nerves, which connect the inner ear to the brain and control both hearing and balance ^[6].
The Impact: Because these tumors occur on both sides (bilateral), they present a unique challenge for hearing preservation ^[7]. As they grow, they can compress the facial nerve, which controls your ability to smile and close your eyes, and can eventually press against the brainstem, which can cause severe neurological complications if not proactively managed ^[2]^[8].

Meningiomas: Tumors of the Brain Lining

About half of the people with NF2-related schwannomatosis will develop one or more meningiomas ^[9].

Location: These grow from the meninges, the protective membranes that surround the brain and spinal cord ^[10].
Growth Patterns: In this condition, meningiomas often appear in “multiples.” While many grow very slowly, their presence is associated with an increased risk of neurological symptoms and higher mortality if they become numerous or large ^[11]^[12].
Management: Doctors often use “serial surveillance” (regular MRIs) to watch these tumors. If they begin to grow or cause symptoms, specialized surgery or targeted radiation may be considered ^[9]^[13].

Ependymomas: Spinal Cord Tumors

Ependymomas are tumors that arise from the cells lining the central canal of the spinal cord ^[14].

Presentation: In NF2, these are often “low-grade” and may stay the same size for years ^[15].
Cystic Changes: Sometimes these tumors develop fluid-filled sacs called cysts. For these specific cases, a medication called bevacizumab has shown promise in reducing the size of the cysts and the pressure they cause ^[16].

Peripheral and Ocular Manifestations

The condition also affects the nerves in your limbs and your vision:

Peripheral Schwannomas: These can feel like hard, sometimes painful bumps under the skin. They can also grow deep within the body on major nerves like the ulnar nerve in the arm ^[17]^[18].
Ocular (Eye) Signs: Beyond tumors, many patients develop juvenile cataracts (clouding of the eye lens) or retinal hamartomas (small, benign growths on the retina) ^[1]. In children, these can sometimes cause a “lazy eye” or unusual eye movements ^[19].

Quality of Life

Living with these manifestations often involves managing more than just tumor size. Many patients experience chronic pain, anxiety, and depression due to the physical changes and the uncertainty of future growth ^[20]^[21]. Specialists often use the NFTI-QOL, a specific questionnaire designed for NF2 patients, to ensure they are treating the person and their daily well-being, not just the “spots” on an MRI ^[22]^[23].

Common questions in this guide

What are bilateral vestibular schwannomas?

Bilateral vestibular schwannomas are benign tumors that grow on the nerves connecting the inner ear to the brain. They are the hallmark sign of NF2-related schwannomatosis and can affect hearing, balance, and facial movement.

Do meningiomas in NF2 always require surgery?

Not always. Doctors often use serial surveillance with regular MRIs to monitor meningiomas. Surgery or targeted radiation may only be recommended if the tumors grow or start causing symptoms.

Can NF2-related schwannomatosis affect my vision?

Yes, many patients with this condition develop juvenile cataracts or small benign growths on the retina called retinal hamartomas. These can sometimes cause a lazy eye or unusual eye movements, especially in children.

How do spinal ependymomas behave in NF2?

Ependymomas in NF2-related schwannomatosis are typically slow-growing tumors on the spinal cord. If they develop fluid-filled cysts, a medication called bevacizumab may be used to reduce pressure and size.

What is the NFTI-QOL questionnaire used for?

The NFTI-QOL is a specific questionnaire used by specialists to measure how NF2-related schwannomatosis affects a patient's overall quality of life. It tracks factors like chronic pain, anxiety, and daily well-being rather than just tumor size.

Curated prompts to bring to your next appointment.

1.Are there any tumors on my spine (ependymomas or spinal schwannomas) that we should be monitoring, even if I have no pain there?
2.What is the specific growth rate of my vestibular schwannomas based on my last two MRIs?
3.If I develop a meningioma, is surgery always the first option, or can we 'watch and wait' if it isn't causing symptoms?
4.How does the location of my tumors currently affect my risk for facial nerve paralysis?
5.Should we use the NFTI-QOL (Quality of Life) tool to track how these tumors are impacting my daily life beyond just their size on a scan?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References (23)

1
Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation.
Plotkin SR, Messiaen L, Legius E, et al.
Genetics in medicine : official journal of the American College of Medical Genetics 2022; (24(9)):1967-1977 doi:10.1016/j.gim.2022.05.007.
PMID: 35674741
2
Targeted Therapies in the Treatment of Vestibular Schwannomas: Current State and New Horizons.
Welling DB
Otolaryngologic clinics of North America 2023; (56(3)):543-556 doi:10.1016/j.otc.2023.02.013.
PMID: 37024334
3
Management of NF2-associated vestibular schwannomas in children and young adults: influence of surgery and clinical factors on tumor volume and growth rate.
Gugel I, Grimm F, Teuber C, et al.
Journal of neurosurgery. Pediatrics 2019; (24(5)):584-592 doi:10.3171/2019.6.PEDS1947.
PMID: 31443078
4
Neurofibromatosis Type 2: Multiple Meningiomatosis and Vestibular Schwannomas on 68 Ga-DOTATATE PET/CT.
Filizoglu N, Ozguven S
Clinical nuclear medicine 2022; (47(11)):e710-e712 doi:10.1097/RLU.0000000000004355.
PMID: 35961372
5
[Neurofibromatosis type 2 in the otorhinolaryngological practice].
Subbotina MV, Berseneva AV
Vestnik otorinolaringologii 2024; (89(1)):37-41 doi:10.17116/otorino20248901137.
PMID: 38506024
6
Genetic Basis and Clinical Management of Schwannomatosis.
Nagasaka S, Phi JH
Journal of Korean Neurosurgical Society 2025; (68(3)):286-293 doi:10.3340/jkns.2025.0001.
PMID: 40049215
7
Intraoperative Cochlear Nerve Monitoring in Vestibular Schwannoma Microsurgery.
Zhan KY, Wick CC
Otolaryngologic clinics of North America 2023; (56(3)):471-482 doi:10.1016/j.otc.2023.02.007.
PMID: 36964094
8
Management of multiple tumors in neurofibromatosis type 2 patients.
Aboukais R, Bonne NX, Baroncini M, et al.
Neuro-Chirurgie 2018; (64(5)):364-369 doi:10.1016/j.neuchi.2014.11.012.
PMID: 26071178
9
Inherited genetic syndromes and meningiomas.
Look A, Lonser RR
Handbook of clinical neurology 2020; (169()):121-129 doi:10.1016/B978-0-12-804280-9.00007-X.
PMID: 32553283
10
Neurofibromatosis 2 in children presenting during the first decade of life.
Gaudioso C, Listernick R, Fisher MJ, et al.
Neurology 2019; (93(10)):e964-e967 doi:10.1212/WNL.0000000000008065.
PMID: 31363058
11
Natural history and volumetric analysis of meningiomas in neurofibromatosis type 2.
Oyem PC, de Andrade EJ, Soni P, et al.
Neurosurgical focus 2022; (52(5)):E5 doi:10.3171/2022.2.FOCUS21779.
PMID: 35535826
12
Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients.
Hexter A, Jones A, Joe H, et al.
Journal of medical genetics 2015; (52(10)):699-705 doi:10.1136/jmedgenet-2015-103290.
PMID: 26275417
13
Surgery versus stereotactic radiosurgery for the treatment of multiple meningiomas in neurofibromatosis type 2: illustrative case and systematic review.
Nguyen T, Chung LK, Sheppard JP, et al.
Neurosurgical review 2019; (42(1)):85-96 doi:10.1007/s10143-017-0904-2.
PMID: 28900754
14
Surgery in NF2-Schwannomatosis.
Kalamarides M, Pathmanaban O, Peyre M, King AT
Familial cancer 2025; (25(1)):6 doi:10.1007/s10689-025-00522-3.
PMID: 41420725
15
Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis.
Bachir S, Shah S, Shapiro S, et al.
International journal of molecular sciences 2021; (22(2)) doi:10.3390/ijms22020690.
PMID: 33445724
16
The clinical, genetic, and immune landscape of meningioma in patients with NF2-schwannomatosis.
Gregory GE, Islim AI, Hannan CJ, et al.
Neuro-oncology advances 2023; (5(Suppl 1)):i94-i104 doi:10.1093/noajnl/vdac127.
PMID: 37287576
17
Distinct Imaging Features of Peripheral Nerve Sheath Tumours in NF2-Related Schwannomatosis: A Case Report.
Hanna K, Cristiana R, Natalie W, et al.
Case reports in neurological medicine 2025; (2025()):6923539 doi:10.1155/crnm/6923539.
PMID: 41113610
18
Surgical Management of Peripheral Nerve Pathology in Patients With Neurofibromatosis Type 2.
Peyre M, Tran S, Parfait B, et al.
Neurosurgery 2023; (92(2)):317-328 doi:10.1227/neu.0000000000002202.
PMID: 36637268
19
[Primary meningioma of the optical nerve sheet in infancy as initial presentation of neurofibromatosis type 2].
Theurer S, Biewald E, Kuchelmeister K, et al.
Der Pathologe 2019; (40(2)):179-184 doi:10.1007/s00292-018-0464-4.
PMID: 30051275
20
Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.
Hamoy-Jimenez G, Kim R, Suppiah S, et al.
Neuro-oncology advances 2020; (2(Suppl 1)):i141-i149 doi:10.1093/noajnl/vdaa003.
PMID: 32642740
21
Quality of life assessment in schwannomatosis - A systematic review.
Lawson McLean AC, Rosahl SK, Lawson McLean A, et al.
Brain & spine 2025; (5()):104279 doi:10.1016/j.bas.2025.104279.
PMID: 40510571
22
Association between patient-reported outcomes and objective disease indices in people with NF2.
Shukla A, Hsu FC, Slobogean B, et al.
Neurology. Clinical practice 2019; (9(4)):322-329 doi:10.1212/CPJ.0000000000000648.
PMID: 31583187
23
Current Recommendations for Patient-Reported Outcome Measures Assessing Domains of Quality of Life in Neurofibromatosis Clinical Trials.
Wolters PL, Vranceanu AM, Thompson HL, et al.
Neurology 2021; (97(7 Suppl 1)):S50-S63 doi:10.1212/WNL.0000000000012421.
PMID: 34230198

This page explains the common tumors and symptoms associated with NF2-related schwannomatosis for educational purposes. Always consult your specialist regarding your specific MRIs, symptom tracking, and treatment options.

Get notified when new evidence is published on Full NF2-related schwannomatosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents